注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Blueprint Medicines Corp是一家全球精準治療公司,正在為癌癥和血液病患者發明藥物。該公司向美國和歐洲的患者提供其已獲批準的藥物,包括AYVAKIT/AYVAKYT (avapritinib)和GAVRETO(pralsetinib),並在全球範圍內推進系統性肥大癥(SM)、肺癌、乳腺癌和其他基因組癌癥以及癌癥免疫療法的多個項目。其管線還包括Elenestinib(BLU-263)(KIT)、AYVAKIT(avapritinib)(KIT)、野生型KIT研究項目、GAVRETO(pralsetinib)(RET),BLU-945(EGFR),BLU-525(EGFR),BLU-451(EGFR第20號外顯子插入),BLU-222(CDK2),AYVAKIT(PDGFRA),GAVRETO(RET),BLU-222(CDK2)和BLU-852(MAP4K1)。該公司正在開發elenestinib(BLU-263),這是一種正在研究的、口服的、強效的和高選擇性的KIT抑製劑,用於治療惰性SM和其他肥大細胞病癥。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Alexis A. Borisy | 51 | 2011 | Co-Founder & Director |
Jeffrey W. Albers | 52 | 2014 | Chairman |
Kathryn Haviland | 47 | 2016 | President, CEO & Director |
Charles L. Sawyers | 64 | - | Member of Scientific Advisory Board |
Brian J. Druker | 68 | - | Member of Scientific Advisory Board |
William C. Hahn | - | - | Member of Scientific Advisory Board |
Nicholas B. Lydon | 67 | 2011 | Member of Scientific Advisory Board & Independent Director |
Mark A. Goldberg | 70 | 2015 | Independent Director |
George Daniel Demetri | 67 | 2012 | Chair of Scientific Advisory Board |
Lonnel Coats | 59 | 2016 | Independent Director |
Scott W. Lowe | - | - | Member of Scientific Advisory Board |
Habib Joseph Dable | 55 | 2022 | Independent Director |
Daniella Beckman | 45 | 2021 | Independent Director |
Lynn Seely | 65 | 2016 | Lead Independent Director |
John Tsai | 57 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核